---
document_datetime: 2025-12-02 06:18:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/taxotere.html
document_name: taxotere.html
version: success
processing_time: 0.1223161
conversion_datetime: 2025-12-27 21:09:21.218134
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Taxotere

[RSS](/en/individual-human-medicine.xml/66175)

##### Authorised

This medicine is authorised for use in the European Union

docetaxel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Taxotere](#news-on)
- [More information on Taxotere](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Taxotere is a cancer medicine used to treat the following types of cancer:

- breast cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with other cancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
- non-small cell lung cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with cisplatin (another cancer medicine) in patients who have not received any treatment for their cancer;
- prostate cancer, when the cancer has spread to other parts of the body (metastatic). Taxotere is used with prednisone or prednisolone (anti-inflammatory medicines) when the cancer cannot be treated by greatly reducing the body's production of testosterone (castration-resistant prostate cancer). It can also be used with androgen-deprivation therapy when hormonal treatment still works (hormone-sensitive prostate cancer);
- gastric adenocarcinoma (a stomach cancer) that has spread in patients who have not received any treatment for their cancer. Taxotere is used with cisplatin and fluorouracil (other cancer medicines);
- head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). Taxotere is used with cisplatin and fluorouracil.

Taxotere contains the active substance docetaxel.

Expand section

Collapse section

## How is Taxotere used?

Taxotere can only be obtained with a prescription and should only be used in units specialising in giving chemotherapy (medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.

Taxotere is given as a 1-hour infusion (drip) into a vein every 3 weeks. The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated and the patient's weight and height. An anti-inflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Taxotere infusion.

The dose of Taxotere may need to be reduced, or treatment interrupted or discontinued, if the patient develops certain side effects.

For more information about using Taxotere, see the package leaflet or contact your doctor or pharmacist.

## How does Taxotere work?

The active substance in Taxotere, docetaxel, belongs to the group of cancer medicines known as taxanes. Docetaxel blocks the ability of cells to break down the internal 'skeleton' that allows them to divide. With the skeleton still in place, the cells cannot divide and they eventually die. Because docetaxel works on dividing cells, it also affects affects non-cancer cells such as blood cells, which can cause side effects.

## What benefits of Taxotere have been shown in studies?

Taxotere has been studied in over 4,000 breast-cancer patients, around 2,000 non-small-cell-lung-cancer patients, around 2,700 prostate cancer patients, 457 gastric adenocarcinoma patients and 897 head- and neck-cancer patients. In most of these studies, Taxotere was combined with other cancer treatments and compared either with the medicines it is used in combination with or with a combination of different treatments. The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived.

Adding Taxotere to other anticancer treatments was effective in all five types of cancer. When used on its own, Taxotere was at least as effective as and sometimes more effective than the comparator medicines in breast cancer, and more effective than best supportive care (any medicines or treatment to help patients, but not other cancer medicines) in lung cancer.

## What are the risks associated with Taxotere?

The most common side effects with Taxotere (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, white blood cells that fight infection), anaemia (low red blood cell counts), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss) and asthenia (weakness). These side effects may be more severe when Taxotere is used with other cancer medicines. For the full list of side effects of Taxotere, see the package leaflet.

Taxotere must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver. For the full list of restrictions, see the package leaflet.

## Why is Taxotere authorised in the EU?

The European Medicines Agency decided that Taxotere's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Taxotere?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Taxotere have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Taxotere are continuously monitored. Side effects reported with Taxotere are carefully evaluated and any necessary action taken to protect patients.

## Other information about Taxotere

Taxotere received a marketing authorisation valid throughout the EU on 27 November 1995.

Taxotere : EPAR - Summary for the public

English (EN) (148.34 KB - PDF)

**First published:** 18/01/2008

**Last updated:** 11/12/2019

[View](/en/documents/overview/taxotere-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-247)

български (BG) (183.18 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/bg/documents/overview/taxotere-epar-summary-public_bg.pdf)

español (ES) (150.83 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/es/documents/overview/taxotere-epar-summary-public_es.pdf)

čeština (CS) (183.46 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/cs/documents/overview/taxotere-epar-summary-public_cs.pdf)

dansk (DA) (150.62 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/da/documents/overview/taxotere-epar-summary-public_da.pdf)

Deutsch (DE) (158.69 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/de/documents/overview/taxotere-epar-summary-public_de.pdf)

eesti keel (ET) (148.35 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/et/documents/overview/taxotere-epar-summary-public_et.pdf)

ελληνικά (EL) (183.11 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/el/documents/overview/taxotere-epar-summary-public_el.pdf)

français (FR) (152.35 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/fr/documents/overview/taxotere-epar-summary-public_fr.pdf)

hrvatski (HR) (173.71 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/hr/documents/overview/taxotere-epar-summary-public_hr.pdf)

italiano (IT) (153.9 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/it/documents/overview/taxotere-epar-summary-public_it.pdf)

latviešu valoda (LV) (190.88 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/lv/documents/overview/taxotere-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (182.26 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/lt/documents/overview/taxotere-epar-summary-public_lt.pdf)

magyar (HU) (172.91 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/hu/documents/overview/taxotere-epar-summary-public_hu.pdf)

Malti (MT) (183.29 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/mt/documents/overview/taxotere-epar-summary-public_mt.pdf)

Nederlands (NL) (150.66 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/nl/documents/overview/taxotere-epar-summary-public_nl.pdf)

polski (PL) (184.08 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/pl/documents/overview/taxotere-epar-summary-public_pl.pdf)

português (PT) (152.79 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/pt/documents/overview/taxotere-epar-summary-public_pt.pdf)

română (RO) (180.13 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/ro/documents/overview/taxotere-epar-summary-public_ro.pdf)

slovenčina (SK) (186.98 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/sk/documents/overview/taxotere-epar-summary-public_sk.pdf)

slovenščina (SL) (172.72 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/sl/documents/overview/taxotere-epar-summary-public_sl.pdf)

Suomi (FI) (152.25 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/fi/documents/overview/taxotere-epar-summary-public_fi.pdf)

svenska (SV) (150.57 KB - PDF)

**First published:**

18/01/2008

**Last updated:**

11/12/2019

[View](/sv/documents/overview/taxotere-epar-summary-public_sv.pdf)

Taxotere : EPAR - Risk-management-plan summary

English (EN) (43.82 KB - PDF)

**First published:** 11/12/2019

**Last updated:** 11/06/2020

[View](/en/documents/rmp-summary/taxotere-epar-risk-management-plan-summary_en.pdf)

## Product information

Taxotere : EPAR - Product Information

English (EN) (2.15 MB - PDF)

**First published:** 13/01/2009

**Last updated:** 31/07/2024

[View](/en/documents/product-information/taxotere-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-145)

български (BG) (3 MB - PDF)

**First published:**

31/07/2024

[View](/bg/documents/product-information/taxotere-epar-product-information_bg.pdf)

español (ES) (2.16 MB - PDF)

**First published:**

31/07/2024

[View](/es/documents/product-information/taxotere-epar-product-information_es.pdf)

čeština (CS) (2.38 MB - PDF)

**First published:**

31/07/2024

[View](/cs/documents/product-information/taxotere-epar-product-information_cs.pdf)

dansk (DA) (2.17 MB - PDF)

**First published:**

31/07/2024

[View](/da/documents/product-information/taxotere-epar-product-information_da.pdf)

Deutsch (DE) (2.38 MB - PDF)

**First published:**

31/07/2024

[View](/de/documents/product-information/taxotere-epar-product-information_de.pdf)

eesti keel (ET) (2.4 MB - PDF)

**First published:**

31/07/2024

[View](/et/documents/product-information/taxotere-epar-product-information_et.pdf)

ελληνικά (EL) (3.09 MB - PDF)

**First published:**

31/07/2024

[View](/el/documents/product-information/taxotere-epar-product-information_el.pdf)

français (FR) (2.44 MB - PDF)

**First published:**

31/07/2024

[View](/fr/documents/product-information/taxotere-epar-product-information_fr.pdf)

hrvatski (HR) (2.56 MB - PDF)

**First published:**

31/07/2024

[View](/hr/documents/product-information/taxotere-epar-product-information_hr.pdf)

íslenska (IS) (2.26 MB - PDF)

**First published:**

31/07/2024

[View](/is/documents/product-information/taxotere-epar-product-information_is.pdf)

italiano (IT) (2.29 MB - PDF)

**First published:**

31/07/2024

[View](/it/documents/product-information/taxotere-epar-product-information_it.pdf)

latviešu valoda (LV) (2.62 MB - PDF)

**First published:**

31/07/2024

[View](/lv/documents/product-information/taxotere-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.79 MB - PDF)

**First published:**

31/07/2024

[View](/lt/documents/product-information/taxotere-epar-product-information_lt.pdf)

magyar (HU) (2.65 MB - PDF)

**First published:**

31/07/2024

[View](/hu/documents/product-information/taxotere-epar-product-information_hu.pdf)

Malti (MT) (3.03 MB - PDF)

**First published:**

31/07/2024

[View](/mt/documents/product-information/taxotere-epar-product-information_mt.pdf)

Nederlands (NL) (2.26 MB - PDF)

**First published:**

31/07/2024

[View](/nl/documents/product-information/taxotere-epar-product-information_nl.pdf)

norsk (NO) (2.19 MB - PDF)

**First published:**

31/07/2024

[View](/no/documents/product-information/taxotere-epar-product-information_no.pdf)

polski (PL) (2.69 MB - PDF)

**First published:**

31/07/2024

[View](/pl/documents/product-information/taxotere-epar-product-information_pl.pdf)

português (PT) (2.1 MB - PDF)

**First published:**

31/07/2024

[View](/pt/documents/product-information/taxotere-epar-product-information_pt.pdf)

română (RO) (2.57 MB - PDF)

**First published:**

31/07/2024

[View](/ro/documents/product-information/taxotere-epar-product-information_ro.pdf)

slovenčina (SK) (2.56 MB - PDF)

**First published:**

31/07/2024

[View](/sk/documents/product-information/taxotere-epar-product-information_sk.pdf)

slovenščina (SL) (2.58 MB - PDF)

**First published:**

31/07/2024

[View](/sl/documents/product-information/taxotere-epar-product-information_sl.pdf)

Suomi (FI) (2.33 MB - PDF)

**First published:**

31/07/2024

[View](/fi/documents/product-information/taxotere-epar-product-information_fi.pdf)

svenska (SV) (2.12 MB - PDF)

**First published:**

31/07/2024

[View](/sv/documents/product-information/taxotere-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/N/0000220958 30/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Taxotere : EPAR - All Authorised presentations

English (EN) (65.62 KB - PDF)

**First published:** 22/12/2005

**Last updated:** 24/06/2010

[View](/en/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-367)

български (BG) (91.43 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/bg/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_bg.pdf)

español (ES) (66.35 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/es/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_es.pdf)

čeština (CS) (93.99 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/cs/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (69.66 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/da/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (70.41 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/de/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (64.27 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/et/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (87.01 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/el/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_el.pdf)

français (FR) (66.32 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/fr/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (64.37 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/it/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (93.21 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/lv/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (87.88 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/lt/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (70.86 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/hu/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (93.06 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/mt/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66.22 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/nl/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_nl.pdf)

polski (PL) (91.56 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/pl/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_pl.pdf)

português (PT) (65.71 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/pt/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_pt.pdf)

română (RO) (87.26 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/ro/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.76 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/sk/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.04 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/sl/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.64 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/fi/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (68.24 KB - PDF)

**First published:**

22/12/2005

**Last updated:**

24/06/2010

[View](/sv/documents/all-authorised-presentations/taxotere-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Taxotere Active substance docetaxel International non-proprietary name (INN) or common name docetaxel Therapeutic area (MeSH)

- Head and Neck Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Prostatic Neoplasms
- Stomach Neoplasms
- Breast Neoplasms

Anatomical therapeutic chemical (ATC) code L01CD02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Breast cancer**

Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

- operable node-positive breast cancer;
- operable node-negative breast cancer.

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.

Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.

Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

**Non-small-cell lung cancer**

Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

**Prostate cancer**

Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

**Gastric adenocarcinoma**

Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

**Head and neck cancer**

Taxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

## Authorisation details

EMA product number EMEA/H/C/000073 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 12/07/1995 Marketing authorisation issued 27/11/1995 Revision 52

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Taxotere : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.04 KB - PDF)

**First published:** 31/07/2024

[View](/en/documents/procedural-steps-after/taxotere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Taxotere : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (470.75 KB - PDF)

**First published:** 16/01/2009

**Last updated:** 31/07/2024

[View](/en/documents/procedural-steps-after/taxotere-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Taxotere-H-C-WS1550 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/647024/2019

English (EN) (4.06 MB - PDF)

**First published:** 11/12/2019

[View](/en/documents/variation-report/taxotere-h-c-ws1550-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Taxotere (WS-1550)

Adopted

Reference Number: EMA/CHMP/510409/2019

English (EN) (74.85 KB - PDF)

**First published:** 20/09/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere-ws-1550_en.pdf)

Taxotere-H-C-PSUSA-00001152-201611 : EPAR - Scientific conclusion and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/841558/2017

English (EN) (69.02 KB - PDF)

**First published:** 20/12/2017

**Last updated:** 20/12/2017

[View](/en/documents/scientific-conclusion/taxotere-h-c-psusa-00001152-201611-epar-scientific-conclusion-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Taxotere-H-C-73-P46-0037 : EPAR - Assessment Report

Adopted

Reference Number: EMA/58475/2013

English (EN) (105 KB - PDF)

**First published:** 14/02/2013

**Last updated:** 14/02/2013

[View](/en/documents/variation-report/taxotere-h-c-73-p46-0037-epar-assessment-report_en.pdf)

Taxotere-H-C-73-II-0090 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/355802/2010

English (EN) (1.12 MB - PDF)

**First published:** 30/07/2010

**Last updated:** 30/07/2010

[View](/en/documents/variation-report/taxotere-h-c-73-ii-0090-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Taxotere

Adopted

English (EN) (59.38 KB - PDF)

**First published:** 21/05/2010

**Last updated:** 21/05/2010

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere_en.pdf)

Taxotere-H-C-73-X-0086 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/774786/2009

English (EN) (71.5 KB - PDF)

**First published:** 02/02/2010

**Last updated:** 02/02/2010

[View](/en/documents/variation-report/taxotere-h-c-73-x-0086-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Taxotere

Adopted

English (EN) (29.42 KB - PDF)

**First published:** 19/11/2009

**Last updated:** 19/11/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere_en.pdf-0)

Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Taxotere / Docetaxel Winthrop

Adopted

Reference Number: EMEA/384759/2008

English (EN) (36.96 KB - PDF)

**First published:** 24/07/2008

**Last updated:** 24/07/2008

[View](/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-taxotere-docetaxel-winthrop_en.pdf)

Taxotere-H-C-73-II-0080 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (675.85 KB - PDF)

**First published:** 18/01/2008

**Last updated:** 18/01/2008

[View](/en/documents/scientific-discussion-variation/taxotere-h-c-73-ii-0080-epar-scientific-discussion-variation_en.pdf)

Taxotere-H-C-73-II-0070 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (353.06 KB - PDF)

**First published:** 06/12/2006

**Last updated:** 06/12/2006

[View](/en/documents/scientific-discussion-variation/taxotere-h-c-73-ii-0070-epar-scientific-discussion-variation_en.pdf)

Taxotere : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (120.07 KB - PDF)

**First published:** 22/12/2005

**Last updated:** 22/12/2005

[View](/en/documents/steps-after-cutoff/taxotere-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Taxotere : EPAR - Scientific Discussion

English (EN) (281.16 KB - PDF)

**First published:** 22/12/2005

**Last updated:** 22/12/2005

[View](/en/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf)

Taxotere : EPAR - Procedural steps taken before authorisation

English (EN) (85.07 KB - PDF)

**First published:** 22/12/2005

**Last updated:** 22/12/2005

[View](/en/documents/procedural-steps/taxotere-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Taxotere

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019) 20/09/2019

[PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel](/en/news/prac-concludes-there-no-evidence-change-known-risk-neutropenic-enterocolitis-docetaxel) 09/06/2017

#### More information on Taxotere

- [Docetaxel - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/docetaxel)
- [Taxotere - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/taxotere)
- [Taxotere - supply shortage](/en/medicines/human/shortages/taxotere)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/07/2024

## Share this page

[Back to top](#main-content)